Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCR-6920 in advanced malignant tumors
NCT05528055Phase 1Recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- May 2022
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SCR-6920 in solid tumor, non-Hodgkin lymphoma (NHL) and non-small cell lung cancer (NSCLC) (4 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Dose limiting toxicity at 28 days and Overall Response Rate at 1 year. Started May 2022; status: recruiting.
02
Drugs
SCR-6920
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05528055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05528055.